The IFIGENEIA project (Horizon Europe, WIDERA) aims to lay the foundations for significant advancements in the production and clinical application of radionuclides using linear accelerators (LINACs), thereby enhancing radiopharmaceutical development and availability across EU countries Greece, Slovenia, and Cyprus. As part of a project focused on radioisotope production and radiopharmaceuticals, we are conducting an essential hospital questionnaire designed to evaluate current practices, identify unmet needs, and guide the integration of novel radionuclides into clinical practice.
The primary goal of this hospital questionnaire is to gain a thorough understanding of the landscape of radiopharmaceutical usage in medical institutions, with a particular focus on diagnostic and therapeutic applications. It seeks insights into the radionuclides currently employed, their clinical indications, the volume of usage, and the specifics of their procurement and administration.
Additionally, the questionnaire aims to uncover challenges hospitals face regarding radionuclide supply, such as shortages or delays, and the subsequent impacts on patient care and clinical workflows. It will also identify radionuclides previously utilised but discontinued due to supply issues, highlighting critical gaps that could potentially be filled through improved LINAC production methods.
Another significant goal is to gauge interest and potential demand for novel or less common radionuclides that hospitals would adopt if supply and cost constraints were addressed. Understanding hospital infrastructure capabilities, including radiolabelling capacities and involvement in clinical or preclinical trials, is also vital. This comprehensive data collection will ultimately inform strategic decisions regarding the production and implementation of radionuclides within the new Excellence Hubs that are being established in Greece, Slovenia, and Cyprus.
The insights gathered through this questionnaire will ensure that future developments closely align with clinical needs, thereby enhancing the efficiency, accessibility, and effectiveness of radiopharmaceutical therapies and diagnostics.
We invite hospitals and nuclear medicine departments across Europe to actively participate in this valuable initiative. Your involvement will directly contribute to optimising radionuclide availability, improving patient outcomes, and driving innovation in nuclear medicine.
Stay updated and engaged by following our progress on social media or contact us via email: mec@mf.uni-lj.si. Help us shape the future of radionuclide therapy and diagnostics by sharing your experiences and needs. Together, we can revolutionise nuclear medicine and improve healthcare outcomes across the region.